🇺🇸 FDA
Patent

US 11421284

Methods for predicting drug responsiveness in cancer patients

granted A61KA61K31/122A61K45/06

Quick answer

US patent 11421284 (Methods for predicting drug responsiveness in cancer patients) held by Allarity Therapeutics Europe ApS expires Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Allarity Therapeutics Europe ApS
Grant date
Tue Aug 23 2022 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Aug 18 2042 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
20
CPC classes
A61K, A61K31/122, A61K45/06, A61K9/0019